BridgeBio Oncology Therapeutics Inc
BBOT
NASDAQ
Biotechnology
$9.06
USD
-0.17 (-1.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $743.39M
Volume 227.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-233.03M
TTM
— YoY
Operating Cash Flow
$-193.14M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 14.1 | 5.3 | 6.4 | 11.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 49.2 | 43.4 | 46.2 | 60.2 |
Operating Income | -49.2 | -43.4 | -46.2 | -60.2 |
EBITDA | -49.0 | -43.0 | -46.0 | -60.0 |
Other Income / Expense | 1.0 | 0.2 | 0.1 | 0.2 |
Total Other Income / Expense | 4.4 | 4.6 | 4.1 | 3.7 |
Income Before Income Taxes | -44.8 | -38.8 | -42.1 | -56.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -95.7 | -38.8 | -42.1 | -56.5 |
Consolidated Net Income / Loss | -44.8 | -38.8 | -42.1 | -56.5 |
Net Income Attributable to Common Shareholders | -44.8 | -38.8 | -42.1 | -56.5 |
Basic EPS | -$1.03 | -$0.48 | -$526.11 | -$705.20 |
Diluted EPS | -$1.03 | -$0.48 | -$526.11 | -$705.20 |
Basic Shares Outstanding | 43.5M | 80.6M | 0.1M | 0.1M |
Diluted Shares Outstanding | 43.5M | 80.6M | 0.1M | 0.1M |